Article By:
ChinaBio® Today
Saturday, August 22, 2020 1:53 PM EDT
Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.
Biotech is Hot Sparked By Biotech M&A Deals for Juno and Bioverativ
I can't believe how high $JUNO has gone up since I've sold it. Big mistake.
Juno Therapeutics Shares Sky Rocket Following Buyout For $9 Billion
I can't believe I used to own this stock. Sold too soon! $JUNO
Biotech Buzz Is Broken
$KITE opened pretty good, $JUNO needs a bounce